Last reviewed · How we verify
OPC-12759
OPC-12759 is a selective dopamine D2 receptor antagonist.
OPC-12759 is a selective dopamine D2 receptor antagonist. Used for Treatment of schizophrenia.
At a glance
| Generic name | OPC-12759 |
|---|---|
| Also known as | rebamipide |
| Sponsor | Otsuka Pharmaceutical Co., Ltd. |
| Drug class | Dopamine D2 receptor antagonist |
| Target | D2 receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
It works by blocking the action of dopamine at D2 receptors in the brain, which is thought to be involved in the pathophysiology of schizophrenia. This blockade is believed to help alleviate symptoms of psychosis and negative symptoms associated with schizophrenia.
Approved indications
- Treatment of schizophrenia
Common side effects
- Orthostatic hypotension
- Somnolence
- Dizziness
Key clinical trials
- Safety Study of OPC-12759 Ophthalmic Solution (PHASE1)
- Confirmatory Study of OPC-12759 Ophthalmic Solution (PHASE3)
- Comparison Between Rebamipide 2% Versus Autologous Serum (PHASE4)
- Exploratory Study of OPC-12759 Ophthalmic Suspension (PHASE2)
- Dose-response Study of OPC-12759 Ophthalmic Suspension (PHASE2)
- Long Term Administration Study of OPC-12759 Ophthalmic Suspension (PHASE3)
- Confirmatory Study of OPC-12759 Ophthalmic Suspension (PHASE3)
- Late Phase 2 Study of OPC-12759 Ophthalmic Suspension (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OPC-12759 CI brief — competitive landscape report
- OPC-12759 updates RSS · CI watch RSS
- Otsuka Pharmaceutical Co., Ltd. portfolio CI